Company intelligence / Profile preview

Alethiomics

Oxford, United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Alethiomics is a pre-clinical company focused on discovering novel drug targets in myeloproliferative neoplasms using single-cell multi-omics. The company's TARGET-seq platform was selected for presentation at the American Society of Haematology (ASH) annual meeting in December 2021.

Therapeutic areas: Oncology
Industry: Biotech

Partnerships

Cancer Research UK

Beyond the preview

Go deeper on Alethiomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alethiomics.

Explore the full profile